Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
Toby A. Maurer, MD
Toby A. Maurer, MD
Professor of Clinical Dermatology
Indiana University
Indianapolis, IN
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Slides
Question of the Week
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
May 5, 2025: Preventing and Managing Syphilis
A 46-year-old man with HIV (plasma HIV RNA <20 copies/mL; CD4+ count, 1100 cells/µL) presented to care with low-grade fever, hair loss, and a rash involving his palms and soles. His treponemal enzyme immunoassay was reactive, as was his serum rapid plasma reagin (RPR) with a titer of 1:64. He was diagnosed with secondary syphilis and treated with 2.4 million units of long-acting benzathine penicillin G intramuscularly. At 3 months, his RPR titer was 1:32. Now, at 6 months, his RPR titer is still 1:32. He denies any symptoms or new exposures since his treatment 6 months ago. Which of the following is the most appropriate approach at 6 months following treatment for early syphilis?
A. No intervention is necessary at this time. Continue to follow the RPR titers
B. Order a cerebrospinal fluid examination (ie, lumbar puncture)
C. Treat with 1 intramuscular dose of 2.4 million units of long-acting benzathine penicillin G
D. Treat with 3 intramuscular doses of 2.4 million units of long-acting benzathine penicillin G, each 1 week apart
Register for the Virtual Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE
